PEGylation and glycosylation as bioconjugation tools for drug development: New webinar tackles complex chemistry for targeted ...
The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...
Munich-based antibody-drug conjugate (ADC) specialist Tubulis has raised an impressive €308 million ($358 million) to help ...
In his award-winning drama The Things You Kill, Iranian-Canadian filmmaker Alireza Khatami explores the inherited weight of fatherhood, masculinity, and political trauma through a narrative set in ...
Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...
News-Medical.Net on MSN
Reimagining light scattering for biotherapeutics
Wyatt Technology's DynaPro Plate Reader 4 integrates advanced light scattering techniques, optimizing workflows in ...
On 16 October, the 2025 Sustainability Global Leaders Conference was held in Shanghai. Themed "Joining Hands to ...
A Phase 1 clinical trial led by researchers at the University of Maryland School of Medicine has demonstrated that a novel ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
Scientists at National Taiwan University (NTU) have developed a pioneering optical microscopy method that can reconstruct a ...
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results